RT Journal Article
SR Electronic
T1 Laboratory validation of an RNA/DNA hybrid tagmentation based mNGS workflow on SARS-CoV-2 and other respiratory RNA viruses detection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.12.20099754
DO 10.1101/2020.05.12.20099754
A1 Wei, Feili
A1 Yu, Yanhua
A1 Hu, Zhongjie
A1 Wang, Rui
A1 Guo, Xianghua
A1 Jin, Haiying
A1 Guo, Shan
A1 Ouyang, Yabo
A1 Shi, Ying
A1 Jin, Ronghua
A1 Chen, Dexi
YR 2020
UL http://medrxiv.org/content/early/2020/05/22/2020.05.12.20099754.abstract
AB Background Acute respiratory infection (ARI) caused by RNA viruses is still one of the main diseases all over the world such as SARS-CoV-2 and Influenza A virus. mNGS was a powerful tool for ethological diagnosis. But there were some challenges during mNGS implementation in clinical settings such as time-consuming manipulation and lack of comprehensive analytical validation.Methods We set up CATCH that was a mNGS method based on RNA and DNA hybrid tagmentation via Tn5 transposon. Seven respiratory RNA viruses and three subtypes of Influenza A virus had been used to test CATCH’s capabilities of detection and semiquantification. Analytical performance of SARS-CoV-2 and Influenza A virus had been determined with reference standards. We compared accuracy of CATCH with quantitative real time PCR by using clinical 98 samples from 64 COVID-19 patients.Results We minimized the library preparation process to 3 hours and handling time to 35 minutes. Duplicate filtered RPM of 7 respiratory viruses and 3 Influenza A virus subtypes were highly correlated with viral concentration (r=0.60, p<0.001, Spearman correlation test). LOD of SARS-CoV-2 was 39.2 copies/test and of Influenza A virus was 278.1 copies/mL Comparing with qR-TPCR, the overall accuracy of CATCH was 91.4%. Sensitivity was 84.5% and specificity was 100%. Meanwhile, there were significant difference of microbial profile in oropharyngeal swabs among critical, moderate patients and healthy controls (p<0.001, PERMANOVA test).Conclusion Although further optimization is needed before CATCH can be rolled out as a routine diagnostic test, we highlight the potential impact of it advancing molecular diagnostics for respiratory pathogens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the COVID-19 Key Technology Research and Development Funding of Beijing Hospital Authority, National Science and Technology Major Special Program of the 13th Five Year Plan (2018ZX10732202-004-003), and Beijing institute of Hepatology Reform and Development Project (Y-2020HZ-2).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Ethics Committee of Beijing Youan Hospital, Capital Medical University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw sequence data of samples in this study, after removal of human reads, will be deposited to Genome Warehouse in National Genomics Data Center and the sequence Read Archive database.